drugset / Trial / NCT06040970
Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, Phase 1 study with a dose expansion cohort of Sacituzumab Govitecan in Combination with Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer. The goal of the study is to determine the optimal dose of sacituzumab govitecan for use in combination with cisplatin for treatment of epithelial ovarian and endometrial cancers.
Timeline
- Start
- 2024-10-23
- Primary completion
- 2026-07-01
- Completion
- 2027-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sacituzumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Sacituzumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Background | Cisplatin | Other / unclassified | 70 mg/m2 | Intravenous |